Head-to-head · WeighScore
Dr. Arevitalize vs Omada Health
The verdict
Dr. Arevitalize takes it — 65.2/100 to 55.6/100.
Dr. Arevitalize grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Dr. Arevitalize (Dr.Arevitalize Health, Inc.) is a LegitScript-certified telehealth platform offering compounded GLP-1 weight-loss medication in both injectable and oral-capsule forms — semaglutide fr
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Dr. Arevitalize | Omada Health |
|---|---|---|
| WeighScore | 65.2/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #225 | #435 |
| Semaglutide | $319/mo (compounded) | Not disclosed |
| Tirzepatide | $359/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #225 · C
Strengths
- Offers both injectable and oral-capsule compounded GLP-1 — a needle-free option many providers do not carry
- Semaglutide from $269/mo and tirzepatide from $349/mo, in 1-, 3-, 6-, and 12-month bundles
- LegitScript-certified; clinician-guided with lab/bloodwork analysis and personalized plans
- Intro pricing on injectable semaglutide ($269, was $319) and oral semaglutide ($299, was $349)
Where it loses points
- Compounded GLP-1s are not FDA-approved finished products
- Compounding pharmacy partner and prescribing clinician are not named on the site
- State availability is not published on the site
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.